Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/940
Title: Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.
Authors: Salunya Tancharoen
ศรัณยา ตันเจริญ
Kikuchi, Kiyoshi
Ito, Takashi
Morimoto-Yamashita, Yoko
Miura, Naoki
Kawahara, Ko-ichi
Maruyama, Ikuro
Murai, Yoshinaka
Tanaka, Eiichiro
Mahidol University. Faculty of Dentistry. Department of Pharmacology
Tanaka, Eiichiro
Keywords: Candesartan;High mobility group box 1;Irbesartan;Receptor for advanced glycation end-products;Stroke;Telmisartan;Open Access article
Issue Date: Sep-2013
Citation: Kikuchi K, Tancharoen S, Ito T, Morimoto-Yamashita Y, Miura N, Kawahara K, et al. Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. Int J Mol Sci. 2013 Sep 13;14(9):18899-924.
Abstract: Stroke is a major cause of mortality and disability worldwide. The main cause of stroke is atherosclerosis, and the most common risk factor for atherosclerosis is hypertension. Therefore, antihypertensive treatments are recommended for the prevention of stroke. Three angiotensin receptor blockers (ARBs), telmisartan, irbesartan and candesartan, inhibit the expression of the receptor for advanced glycation end-products (RAGE), which is one of the pleiotropic effects of these drugs. High mobility group box 1 (HMGB1) is the ligand of RAGE, and has been recently identified as a lethal mediator of severe sepsis. HMGB1 is an intracellular protein, which acts as an inflammatory cytokine when released into the extracellular milieu. Extracellular HMGB1 causes multiple organ failure and contributes to the pathogenesis of hypertension, hyperlipidemia, diabetes mellitus, atherosclerosis, thrombosis, and stroke. This is the first review of the literature evaluating the potential of three ARBs for the HMGB1-RAGE axis on stroke therapy, including prevention and acute treatment. This review covers clinical and experimental studies conducted between 1976 and 2013. We propose that ARBs, which inhibit the HMGB1/RAGE axis, may offer a novel option for prevention and acute treatment of stroke. However, additional clinical studies are necessary to verify the efficacy of ARBs.
URI: http://repository.li.mahidol.ac.th/dspace/handle/123456789/940
metadata.dc.identifier.url: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794813/pdf/ijms-14-18899.pdf
ISSN: 1422-0067 (electronic)
Appears in Collections:DT-Article

Files in This Item:
File Description SizeFormat 
dt-ar-salunya-2013.pdf289.94 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.